Rarity Bioscience AB is a medical technology manufacturer based in Uppsala that specializes in mutation detection and enhancing liquid biopsy capabilities. The company utilizes its proprietary superRCA® technology to develop innovative solutions aimed at improving diagnostic processes in cancer research and treatment. Rarity Bioscience is recognized for its contributions to the field, having received the Disruptive Technology Award for its advancements in medical technology.
The organization is led by a team of industry experts, including Andrea Ballagi, and is committed to unlocking the full potential of genetic testing. Rarity Bioscience is actively engaged in ongoing research and development initiatives to further its mission. As part of its growth strategy, the company is expanding its operations into the United States, aiming to broaden its impact in the medical technology sector.